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Abstract: Connective tissue is known to provide structural and functional “glue” properties to other
tissues. It contains cellular and molecular components that are arranged in several dynamic
organizations. Connective tissue is the focus of numerous genetic and nongenetic diseases.
Genetic diseases of the connective tissue are minority or rare, but no less important than the
nongenetic diseases. Here we review the impact of reactive oxygen species (ROS) and oxidative stress
on the onset and/or progression of diseases that directly affect connective tissue and have a genetic
origin. It is important to consider that ROS and oxidative stress are not synonymous, although they
are often closely linked. In a normal range, ROS have a relevant physiological role, whose levels
result from a fine balance between ROS producers and ROS scavenge enzymatic systems. However,
pathology arises or worsens when such balance is lost, like when ROS production is abnormally and
constantly high and/or when ROS scavenge (enzymatic) systems are impaired. These concepts apply
to numerous diseases, and connective tissue is no exception. We have organized this review around
the two basic structural molecular components of connective tissue: The ground substance and fibers
(collagen and elastic fibers).
Keywords: connective tissue; reactive oxigen species; oxidative stress; collagen; elastin; fibrilin;
ground substance; collagen fibres; elastic fibres; genetic diseases
1. Introduction
Connective tissue (CT) is the body’s structural support and a dynamic site for other important
functions. For example, it is a medium for the exchange of metabolites; the defense, protection,
and repair of the body; the storage and mobilization of energy (fat); the regulation and integration of
mechanical and cell-signaling responses; the storage and mobilization of growth and differentiation
factors; and a guide and barrier for cell locomotion and migration [1]. CT tightly interacts with other
tissues to maintain functional organs. Most CTs originate from the mesoderm. From this embryonic
layer, pluripotent mesenchymal cells are formed that migrate throughout the embryo, giving rise to
adult CT cells, such as cartilage, bone, tendons, blood, and hematopoietic and lymphoid cells. CT is a
major meeting point of metabolic and catabolic reactions of tissues and organs and a large platform
of signaling that regulates them. One of the most general and significant processes is redox stress,
which involves free radicals. Free radicals are by-products of a wide variety of physiological reactions
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that play crucial roles in living organisms at low concentrations. There is a fine equilibrium between
their formation and degradation in tissues and organ systems, contributing to maintaining these species
under nonpathological levels to preserve healthy homeostasis. However, the excessive accumulation
of these mediators causes oxidative stress, which promotes, among other effects, CT injury.
This review addresses the involvement of oxidative stress in the pathogenesis and progression of
connective tissue genetic diseases, of which most of them belong to the large family of rare diseases.
Being “rare” does not mean that they have lesser importance in the clinical practice, and often their
study reveals crucial physiological mechanisms occurring in health and other more common diseases.
There are, indeed, other CT-associated diseases of nongenetic origin such as arthrosis, arthritis,
and fibrosis, among others, in which ROS and oxidative stress also participate, but they are not going
to be reviewed here because of space limitations.
1.1. Basic Structural Organization, Function, and Cellular and Molecular Components of Connective Tissue
CT is composed of cells and their surrounding extracellular matrix (ECM), which in turn consists
of ground substance (proteoglycans, glycosaminoglycans (GAGs), and nonfibrotic/cell adhesion
glycoproteins) and fibers (collagen and elastic fibers). Depending on the CT, cells, ground substance,
or fibers are the predominant component and determine the histological classification. Fibroblasts are
predominant in loose CT, fibers in tendons and ligaments, and ground substance in embryonic CT.
Nonetheless, all three components are critical for the function of CT(s) in organs.
1.1.1. Cellular Components
The CT is composed of resident and transient cellular components [2]. The most representative
of the former group is the fibroblast [3]. Transient cells are those that (relatively) freely wander and
move in and out of the tissue. Transient cells are almost exclusively represented by leukocytes and
macrophages. Fibroblasts are the most abundant resident cell type of proper CT and are responsible for
synthesizing almost all ECM components. Fibroblasts undergo different states of activity. Those that are
highly active have an elongated morphology, with high transcriptomic activity. In contrast, when cells
are scarcely active (called fibrocytes) they become smaller and have low transcriptomic activity. In both
physiological states, cells are tightly associated with ground substance components and with collagen
and elastic fibers (see below). Fibroblasts undergo cell division and restricted movement and can
differentiate to other cell types such as adipocytes, osteoblasts, and myofibroblasts. In pathological
circumstances, they can also be converted into epithelioid cells through the mesenchymal–epithelial
transition (MET) mechanism. The reverse process, called epithelial–mesenchymal transition (EMT),
also occurs and is relevant in cancer [4,5]. Myofibroblasts are modified fibroblasts that express
some characteristic proteins of smooth muscle cells (SMCs) (some actin-based cytoskeleton proteins).
Myofibroblasts acquire special relevance in wound healing and fibrotic processes [6].
1.1.2. ECM Components
ECM is composed of a large variety of complex macromolecules localized in the extracellular
space of the cells [7]. The extent of ECM varies with the tissue type. Cells maintain their associations
with the ECM by forming specialized junctions that hold them to the surrounding macromolecules.
ECM is not only the skeleton of tissues but also (1) modulates and determines the morphology and
function of fixed and resident cells (see above), (2) influences their development and differentiation
state, (3) regulates their migration and mitotic activity, (4) senses and transduces mechanical forces
(compression and tensile) to cells, (5) facilitates junctional associations among cells, and (6) provides
a biological field for immune defense. As indicated above, ECM is composed of a hydrated gel-like
ground substance embedded with fibers. Ground substance resists compression forces and facilitates a
quick exchange of metabolites and catabolites, whereas fibers support tensile forces.
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Ground Substance
It is composed of GAGs, proteoglycans (GAGs linked to a protein core), and cell
adhesive glycoproteins, also called nonfibrotic glycoproteins. GAGs are long, inflexible,
unbranched polysaccharides composed of chains of repeating disaccharide units, an amino sugar
(N-acetylglucosamine or N-acetylgalactosamine), and a uronic acid (iduronic or glucuronic) [8].
GAGs are classified into four groups, depending on their core disaccharide constituents [9]. GAGs are
strongly negatively charged, attracting cations (such as K+, Na+), which, in turn, attract water that
hydrates ECM and helps to resist compression forces. Unlike hyaluronic acid, GAGs are sulfated and
usually consist of fewer than 300 repeating disaccharide units. The main sulfated GAGs include keratan
sulfate, heparan sulfate, heparin, chondroitin 4-sulfate, chondroitin 6-sulfate, and dermatan sulfate.
These GAGs are usually linked covalently to a core protein to form proteoglycans. An exception is
hyaluronic acid that contains up to 10,000 repeating disaccharide units but does not form covalent
links to some protein molecules. All GAGs are synthesized in the Golgi apparatus with the exception
again of hyaluronic acid, which is synthesized as a polymer at the cytoplasmic face of the plasma
membrane by hyaluronan synthases. Hyaluronic acid also has intracellular functions such as helping
chromosome alignment during mitosis.
Proteoglycans are large structures that look like a bottle brush. They range from about 50,000 Da
(decorin and betaglycan) to as large as 3 million Da (aggrecan) [9,10]. Aggrecan is responsible for
the gel state of the ECM and acts as a barrier to fast diffusion of molecules [11]. Proteoglycans resist
compression and can facilitate normal cellular locomotion of migrating cells to move between these
hydrated macromolecules. At the same time, they can limit the migration of invasive microorganisms
and metastatic cells. Proteoglycans also bind some signaling molecules and assist in the formation
of collagen fibers (decorin). Syndecans are proteoglycans that remain attached to the cell membrane.
Syndecans and betaglycans also act as low-affinity receptors (co-receptors) binding growth factors such
as fibroblast growth factor (FGF) and tumor growth factor-beta (TGF-β), respectively, presenting them
to their respective high-affinity receptors located in the vicinity at the plasma membrane. Moreover,
they also act as hijackers of growth factors, regulating their availability for high-affinity signaling
receptors [12–15].
Nonfiber glycoproteins or cell adhesive glycoproteins are also large macromolecules that have
several domains in their 3D structure. At least one of the domains binds to the cell surface. The most
representative of these glycoproteins are integrins, which bind to collagen fibers and proteoglycans [16,17].
In this manner, cell adhesion glycoproteins help cells to adhere to the extracellular matrix and hold
various components of tissues to each other. Other major types of adhesive glycoproteins are fibronectin,
laminin, entactin, tenascin, chondronectin, and osteonectin.
Fibers
Fibers of ECM provide tensile strength and elasticity. From the molecular perspective, there are
only two types of fibers (collagenous and elastic), whereas from the histochemical point of view three
types are defined (collagenous, reticular, and elastic fibers) [18].
Collagens
Collagen fibers are responsible for compressive forces, together with GAGs and proteoglycans.
Collagen is a hard, inelastic glycoprotein that constitutes an abundant, large family of macromolecules
with over 30 members. The most known and widely expressed are types I, II, III, IV, VII, VIII, IX,
XI, XII, XV, and XVIII [19,20]. Collagen fiber is the result of the regular assembly of tropocollagen
molecules, which are composed of three polypeptide α-chains. Alpha-chains are highly enriched in
glycine, proline, hydroxyproline, and hydroxylysine, and each chain is coded by a single gene [21].
As indicated above, 30 types of collagens have been reported so far and they are grouped into four
categories [22]. The first category is fibril-forming collagens, which have been taken as a model to report
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the basic structure and synthesis. Characteristic collagens of this group are types I, II, III, V, and XI [23].
The second category is fibril-associated collagens, which stabilize the previous group because they
form molecular bridges between fibril-forming collagens and components of the ground substance.
They are composed of types IX and XII. The third is network-forming collagens, which are synthesized
by epithelial cells. As indicated above, they are not subjected to the action of procollagen peptidase
and, consequently, form a network of thin 3D sheets. Examples are collagens IV (characteristic of
basement membrane) and VII, which assist as anchoring fibers in the stabilization of the basement
membrane. The fourth category is transmembrane collagens or collagen-like proteins, which are
integral membrane proteins that participate in adhesion between tissues. This is the case of collagen
type XVII that acts at the epidermis and the dermis, at the level of hemidesmosomes. Other collagens
of this category are types XIII, XXIII, and XXV.
Collagens are synthetized in the ER by translation of the respective mRNA transcripts, generating a
preprocollagen molecule whose proline and lysine residues are co-translationally hydroxylated by
peptidyl proline and lysine hydroxylase, respectively [24]. Three preprocollagen molecules are aligned
and assembled with the help of chaperones in the lumen of RER to form the procollagen molecule.
Next, procollagen molecules leave the RER to the Golgi apparatus using large and pleomorphic
transport carriers, where they are additionally glycosylated to be finally packaged in the trans-Golgi
network and transported to the extracellular space. As procollagen is released to outside of the cell,
extracellular plasma membrane-attached procollagen peptidases remove both amino and carboxyl
ends of propeptides, resulting in a tropocollagen moiety. Tropocollagen molecules spontaneously
self-assemble and align into a regular fibril array only in fibril-forming collagens. The resulting
extracellular basic fibrillar structure of these collagens is subsequently thickened and stabilized
(3D self-assembling) by covalent bonds between lysine and hydroxylysine residues of neighboring
tropocollagen molecules by lysyl oxidases (LOXes) [25]. Importantly, the alignment of collagen fibrils
and fiber bundles is determined by fibroblasts at the plasma membrane level, which act as a mold
for the final correct direction of collagen fibrils. Subsequently, mechanical forces to cells will finally
rearrange the orientation and organization of fibrils and bundles in the tissue [26]. Importantly,
the aforementioned fibrillar structure for fibril-forming collagens is absent in types IV and VII collagen
because propeptides are not removed from procollagen. In this case, the procollagen molecules
assemble only into dimers, forming net-like structures.
Elastic Fibers
Elastic fibers provide most of the elasticity of CT. Elastic fibers are differently organized depending
on the tissue to form long, worm-like, thin fibers, fenestrated sheets (the tunica media of large
elastic arteries and internal elastic lamina of small arteries), or coarse bundles in dermis and elastic
cartilage [27,28]. Fibroblasts and vascular SMCs (VSMCs) synthesize all components of elastic fibers.
Elastin is a glycoprotein that is rich in glycine, lysine, alanine, valine, proline, and desmosine
(only in elastin) residues. However, unlike collagens, elastin does not contain hydroxylysine [29].
Like collagen, elastin comes from a soluble protein precursor, tropoelastin, which becomes insoluble
because of cross-linking of lysine residues by LOXes [25]. Desmosine is highly deformable and,
consequently, provides elasticity to elastic fibers, which explains cycles of stretching and recoiling.
Elastin does not form elastic fibers unless the amorphous central elastin core is surrounded by a
fibrillin-1 microfibril sheath [30]. During elastogenesis, besides fibrillin-1, several fibrillin-binding
proteins facilitate the assembly of elastic fibers and their function, such as latent TGF-β binding
proteins, fibulins, microfibril-associated glycoproteins (MAGPs), a disintegrin and metalloprotease
with thrombospondin type-1 repeats (ADAMTS) and ADAMTS-like (ADAMTSL) proteins, and type
VIII collagen, which limits the amount of stretching of elastic fibers. Transglutaminases and LOXes
are also essential determinants of the final assembly and cross-linking of elastin and deposition onto
microfibril scaffolds. Fibrillin-1 microfibrils interact with growth factors (TGF-βs and BMPs) and
integrins. Fibrilin-1 mutations cause heritable connective tissue diseases, grouped as fibrillinopathies
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(see later). Several fibrillin-binding proteins have been reported. The most representative are latent
TGFβ protein, fibulins 4 and 5, ADAMTS 6 and 10, ADAMTSL 2, aggrecan, MAGP-1 and 2, perlecan,
aggecan, integrins αV, and LOX [31].
Other ECM Components
Finally, other parts of ECM are (1) the basement membrane, which forms the interface between
epithelium and CT, and (2) integrins and dystroglycans, transmembrane glycoproteins that act
as nonsignaling receptors of nonfibrillar/cell adhesive glycoproteins of the ECM and assist in the
structure of basement membrane and CTs. Integrins function in adhesion and signal transduction from
extracellular to intracellular media, activating second messengers at the focal adhesions.
1.2. Maintenance and Turnover of ECM
ECM is slowly but continuously (re)modelled for maintenance and adaptation to local homeostasis
and pathological environments. Major components that are responsible for maintenance and turnover
of ECM are a large family of proteases and their inhibitors, which are both secreted by fibroblasts,
local and transient macrophages, some translocated leukocytes, and metastatic cells. Metalloproteases
(MMPs), transmembrane inhibitors of proteases (TIMPS), soluble cathepsins, and other types of
proteases belong to this group of ECM components [32–35].
1.3. Pathologies Associated with the Connective Tissue
As in any other tissue and organ, connective tissue is susceptible to damage, which is primary
if it originates in some of the cell components or in any of the numerous ECM components and
secondary because of alterations in any of the associated functions such as the metastatic process,
immune overreactions, etc. In this section, we only review pathologies in which redox stress contributes
to their evolution and that arise from damage in genes coding ECM components.
2. Redox and Oxidative Stress: Basic Concepts, Components, and Regulatory Pathways
2.1. Biochemistry of Free Radicals
Free radicals are atoms or molecules containing one or more unpaired electron(s) in the outer shell
(valence shell). The unpaired electron(s) confers specific chemical properties on these molecules, such as
the capacity to subtract electrons from other compounds to obtain stability [36]. However, this process
transforms the molecule that loses its electron(s), so that it becomes a free radical itself, which may lead
to modification of its own function and the function of other molecules. Additionally, molecules with
unpaired electron(s) are short-lived and highly reactive because they are energetically unstable.
Free radicals include molecules that are either positively or negatively charged or electrically neutral
and may be organic or inorganic. Redox reactions involve oxidations and reductions. Oxidation means
the gain of oxygen (O2) by a substance or the loss of an electron, while reduction mean the loss of O2,
the gain of an electron, or the gain of hydrogen [37,38].
Reactive oxygen species (ROS) are small molecules formed by partial reduction of molecular O2,
which participates in crucial biological processes such as cellular respiration and aerobic metabolism.
However, O2 is a Janus-faced molecule, since reactive O2 intermediates are easily converted into
toxic compounds that can cause cell damage through oxidation of proteins, lipids, carbohydrates,
and nucleic acids. Singlet oxygen (1O2), O2•−, and H2O2 are the primary ROS products generated after
the partial reduction of O2, while hydroxyl radical (OH•) and hypochlorous acid (HOCl) are generated
in subsequent reactions [39]. O2•− contains an unpaired electron and is a negatively charged species that
does not diffuse across biological membranes. O2•− may react rapidly with (1) Fe−S clusters, which can
generate H2O2, (2) Fe2+, which can form OH• by the Fenton reaction, and (3) superoxide dismutase
(SOD), which dismutates O2•− to form H2O2 and O2. On the other hand, the formation of HOCl and
1O2 can occur because of the catalytic activity of peroxidases (e.g., myeloperoxidase). The Haber–Weiss
Antioxidants 2020, 9, 1013 6 of 39
reaction, which includes the Fenton reaction, uses Fe2+ to generate the highly reactive oxidant OH•,
when O2•− and H2O2 are not metabolized. Notably, O2•− can react with NO, at a diffusion-limited rate,
to produce the highly reactive and harmful peroxynitrite (ONOO•−), which is either a nitrogen- or
oxygen-centered radical species [40]. H2O2 is not a free radical. It is more stable than O2•− and it can
cross membranes through aquaporins [41]. H2O2 is produced constitutively in the mitochondria [42],
in the membrane of the ER [43], and by NADPH oxidase NOX4 [44]. Other important sources of
H2O2 result from the dismutation of O2•− spontaneously or enzymatically via superoxide dismutase
(SOD) [45].
2.2. Main Enzymatic Sources of Free Radicals
Endogenous free radicals are produced in environments of high O2 consumption, which mainly
include intracellular organelles such as mitochondria, endoplasmic reticulum (ER), and peroxisomes.
They are also produced in locations like the plasma membrane. The main endogenous enzymatic
sources of ROS in mammals include (1) the mitochondrial respiratory chain, (2) cytochrome P450,
(3) the flavoenzyme Ero1, (4) NADPH oxidases, (5) xanthine oxidase (XO), (6) lipoxygenases, (7) nitric
oxide synthases (NOS), and (8) cyclooxygenases (COXes).
In the mitochondria, ATP is formed by oxidative phosphorylation, a process in which O2 is
reduced to H2O along the electron transport chain. Under these circumstances, O2•− is produced
in several reactions catalyzed by enzymes in the internal membrane of mitochondria, where the
greatest O2•−-generating capacity sites are complexes I and III [46]. Another source is the catalytic
cycle of cytochrome P450, which metabolizes organic substrates principally via oxidations and
involves the use of O2, giving rise to O2•− and H2O2 as by-products [47]. Other enzymatic sources
of mitochondrial ROS are NADH-cytochrome β5 reductase [48], dihydroorotate dehydrogenase [49],
complex II (succinate dehydrogenase) [50], and monoamine oxidases [51].
The ER also produces ROS because of protein-folding processes, NADPH oxidase enzymes,
and flavoenzyme Ero1 activity. The last is an ER-resident oxidase responsible for disulfide bond
formation to achieve oxidative folding of proteins [52]. In this process, O2 is consumed and H2O2 is
produced as a by-product. When oxidative stress rises, it can increase Ca2+ leak from the ER lumen,
which in turn stimulates mitochondrial ROS production [53].
The NOX family of catalytic subunits of NADPH oxidase are transmembrane-bound redox
enzymes that represent the main source of ROS in vascular tissue, though they are also present in
nonvascular tissues. The catalytic function of NOX isoforms is the reduction of O2 in the presence of
NADPH to generate O2•− and other ROS. In most mammals, the NOX family involves seven isoforms:
NOX1–5, DUOX1, and DUOX2. All of them act as transmembrane catalytic subunits, but have
different levels of action [54]. NOX-1–3 are activated by effector proteins (i.e., GTP Rac, NOXO1,
NOXA1, p22phox, p40phox, p47phox and p67phox) to assemble large functionally active complexes,
while NOX4 is constitutively active and is regulated mainly by its level of expression by Poldip 2 [55].
NOX5 and DUOX1 and 2 are Ca2+-activated isoforms [56]. Unlike NOX3, the rest of the NOXes are all
expressed in the cardiovascular system [57]. In addition, NOX5 is only expressed in human cells [58].
NOX isoforms localize to the plasma membrane, caveolae, endosomes, focal adhesions, ER, nucleus,
and mitochondria [59]. Regarding the specific ROS produced by these enzymes, NOXes1 and 3 and
NOX5 generate O2•−, while NOX4, DUOX1, and DUOX2 produce H2O2 [55].
On the other hand, XO is a soluble, membrane-bound O2•−- and H2O2-generating enzyme that
plays a crucial role in the catabolism of purine nucleotides. It catalyzes the oxidation of hypoxanthine
to xanthine and can further catalyze the oxidation of xanthine to uric acid (UA) [60]. Notably, when it
accumulates, UA can be a pro-oxidant, but at physiological levels, it is the most potent non-enzymatic
antioxidant in human plasma [61].
Other sources of ROS include lipoxygenases that catalyze the conversion of polyunsaturated
fatty acids into leukotrienes and lipoxins, which mediate important cellular signaling pathways [62].
These enzymes generate O2•− in the presence of reducing co-substrates [63]. NOS are the most
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important source of nitric oxide (NO) in biological systems. NO is a free radical and a potent
vasodilator with many other relevant physiological functions. Three isoforms of NOS are known [64]:
(1) Neuronal NOS (nNOS or NOS1), whose expression goes beyond neural tissue, (2) inducible NOS
(iNOS or NOS2), whose expression is stimulated by inflammatory stimuli, and (3) endothelial NOS
(eNOS or NOS3), predominantly located in endothelial cells and crucial to maintaining vascular
homeostasis. These enzymes synthesize NO and use L-arginine as the substrate and O2 and NADPH
as co-substrates. The eNOS/NOS3 also has the potential to generate O2•− when some of its cofactors,
tetrahydrobiopterin and L-arginine, are below physiological levels. This process is known as eNOS
uncoupling [65]. Therefore, this phenomenon reduces NO synthesis and increases O2•−-formation,
which in turn may scavenge NO to reduce its availability, leading to impaired NO-dependent
relaxations and the formation of peroxynitrite (ONOO•−), an extremely toxic ROS that further
exacerbate vascular injury.
Finally, COXes are the enzymes that generate prostanoids after oxidation of arachidonic acid,
a polyunsaturated fatty acid present in the phospholipids. Two isoforms of COXes are reported:
The constitutive isoform COX-1 and COX-2, which is generally induced by inflammatory stimuli and
other mediators such as angiotensin II or endothelin-1 [66–68]. COXes generate ROS via oxidation
of substances like NADPH [69] or their products (i.e., prostanoids), which may act as autocrine ROS
stimulators [70].
2.3. Elimination of Free Radicals
Free radical levels are regulated by endogenous enzymatic and non-enzymatic antioxidant
defense systems to prevent their accumulation and maintain cell redox homeostasis.
Tripeptide glutathione, vitamins C and E, and UA provide non-enzymatic antioxidant mechanisms.
However, antioxidant enzymes such as SOD, glutathione peroxidase, glutathione reductase,
glutathione S-transferase, catalase (CAT), peroxiredoxins, and thioredoxin reductase are the
most representative and provide the most specialized enzymatic antioxidant mechanisms in
mammalian tissues.
There are three isoforms of SOD (SODs1–3) that dismutate O2•− into H2O2 and O2 [71].
SOD1 (Cu/Zn) and SOD2 (Mn) are ubiquitous and, respectively, catalyze the dismutation of cytosolic
and mitochondrial, or only mitochondrial, O2•−. Because it is secreted to extracellular spaces and
anchored to the ECM, SOD3 (Cy/Zn) dismutates O2•− in the extracellular space. SOD3 is highly
expressed in vascular, lung, and kidney tissue. Catalase, glutathione peroxidase, thioredoxin reductase,
and peroxiredoxin catalyze the removal of H2O2, which contributes to maintaining the equilibrium of
this molecule [72]. Catalase, which is predominantly expressed in liver and erythrocyte peroxisomes
in mammals, induces the breakdown of H2O2 to H2O and O2, but also H2O2 to H2O by oxidizing
hydrogen-donating compounds [73]. Glutathione peroxidase and glutathione S-transferase reduce
hydroperoxides, using glutathione as an electron donor. There are eight glutathione peroxidase
isoforms with different tissue distribution [71]. Thioredoxin reductase catalyzes the reduction of
thioredoxin using NADPH and participates in the reduction of hydroperoxides and in maintaining
proteins in their reduced state [74]. Peroxiredoxins exist in six subfamily enzymes that are ubiquitously
expressed. In general, these enzymes have peroxidase activity on peroxide substrates (e.g., H2O2,
alkyl hydroperoxides, ONOO•−) using NADPH as the source of reducing equivalents and a thioredoxin
system with the exception of peroxiredoxin 6, which uses glutathione peroxidase as the reductant [71,75].
Antioxidant response elements (AREs) are key components to cellular redox homeostasis in the
reduction of oxidative stress episodes. The activation of these gene expression regulatory elements
triggers fundamental antioxidant responses mediated by the expression of detoxification genes [76].
Multiple transcription factors interact with AREs to activate them and include nuclear factor erythroid
2-related factors 1, 2, and 3 (Nrf1, Nrf2, and Nrf3), small musculoaponeurotic fibrosarcoma proteins
broad-complex, Tramtrack and Bric-a-brac, and cap’n’collar homology proteins, activating transcription
factor 4, JUN proteins, and c-FOS and FRA proteins [76]. One of the most important transcription factors
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that combat oxidative stress through the activation of AREs is Nrf2 [77,78]. KEAP1 is a repressor of
NRF2 under homeostasis but, under stress conditions, NRF2 dissociates from KEAP1 and is translocated
into the nucleus. This mechanism permits the binding of NRF2 to AREs, which leads to the regulation
of gene expression of a wide repertoire of enzymes that metabolize oxidants, including glutathione
S-transferase, NADPH dehydrogenase (quinone 1), SODs, peroxiredoxin, catalase, and glutathione
peroxidase genes [79–81]. Notably, activation of the Nrf2 pathway by exogenous compounds is
possible [82] and can be potentially useful in the treatment of cardiovascular diseases [81,83].
2.4. Detection of Free Radicals
A wide variety of detection methods are available to measure free radical levels. These methods
have advantages and disadvantages that depend on multiple factors and, thus, an exhaustive review
was beyond the scope of this text. Here we briefly describe some of the most common techniques used
to detect biomarkers of oxidative stress; for a more complete overview, the reader is referred to [84–86].
Free radical levels can be measured, among others, by chemiluminescent and fluorescent
probes, chromatography methods, electrochemical biosensors, fluorescent proteins, spectrophotometry
methods, and electron spins resonance [86]. It is worth noting that the results obtained by a single
technique should be used with extreme caution and, whenever possible, validation by another technique
and, whenever applicable, determination of the ROS-forming enzymatic source expression should be
pursued. Lipid peroxidation is commonly used as a marker of oxidative stress because this process is
involved in a variety of acute and chronic diseases. Malondialdehyde and trans-4-hydroxy-2-nonenal
are routinely used as biomarkers of lipid peroxidation [87]. However, for example, the analysis of
F2-isoprostanes levels is more robust because they are more stable molecules produced by nonenzymatic
free radical-catalyzed peroxidation of arachidonic acid [88]. Tyrosine nitration is defined as the addition
of a nitro group in the aromatic ring of tyrosine residues. Analysis of nitrotyrosine levels is often used as
a measure of oxidative/nitrative stress, since nitrotyrosine is a relatively stable biomarker that correlates
with disease activity and its levels decrease with therapeutic interventions. Commonly used techniques
to measure nitrotyrosine levels include liquid chromatography, enzyme-linked immunosorbent assay,
Western blot, and immunofluorescence [85]. Another form of stable oxidative modification of proteins
is the formation of protein carbonyls, which are usually detected spectrophotometrically, or by
enzyme-linked immunosorbent assay, Western blot, immunohistochemistry, or by high-performance
liquid chromatography [85]. Dihydroethidium is a widely used fluorogenic probe to evaluate
“in situ” oxidative stress production. Dihydroethidium is oxidized by numerous oxidants (e.g., O2•−,
H2O2, ONOO−, OH•) to yield ethidium and 2-hydroxyethidium, which accumulate in cells and
emit red (610 nm) fluorescence when interacting with DNA [89]. Interestingly, 2-hydroxyethidium
constitutes a specific measure of O2•−-induced oxidation of dihydroethidium that can be measured by
high-performance liquid chromatography [90].
3. Redox and Oxidative Stress in Genetic Diseases of Connective Tissue
We next discuss only the genetic diseases in which redox and oxidative stress has been reported
so far. Table 1 summarizes each disease, its OMIN and ORPHAN numbers, the causative gene, and the
radical species involved.
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Table 1. Summary of the genetic diseases in which connective tissue molecular components are affected, their causative gene with OMIN and ORPHAN numbers, the
radical species involved and reported therapeutic approaches.








Urinary HO-1 and H2O2; mitochondrial ROS;

















myopathy (MSMP) 255600 289380
Fuchs syndrome (FS) COL8A2 136800 98974
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Aortic tortuosity
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Dehydroascorbate transport
dysfunction-induced ROS increase
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Table 1. Cont.
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3.1. Genetic Diseases Affecting Collagen Fibers and Associated Components
Collagens are associated with a wide variety of diseases for which treatments are needed.
Here, we provide a brief overview of recent progress in mechanisms of disease related to oxidative
stress caused by mutations in collagens and the development of therapeutic strategies.
3.1.1. Collagen IV-Associated Pathologies: Alport Syndrome
Alport syndrome (AS) is an inherited chronic kidney disease, characterized by nephritic symptoms
that appear during early life and progressive impairment of renal function, leading to end-stage renal
disease. Three distinct genetic forms of the disorder exist: (1) X-linked Alport syndrome, linked to
mutations in the COL4A5 gene, (2) autosomal recessive Alport syndrome with mutations in both
alleles of COL4A3 or COL4A4 genes, and (3) autosomal dominant Alport syndrome also associated
with heterozygous mutations in the COL4A3 or COL4A4 genes. Because COL4A5 is located on the X
chromosome, AS1 occurs more commonly in males and the condition usually progresses to end-stage
renal disease by the age of 40 years [91]. However, the detailed mechanism of progression to end-stage
renal disease has not been elucidated. Therefore, children or adults with AS have no specific treatment
and the current therapy is the normalization of blood pressure and reduction of urine protein excretion
to slow the rate of progression toward end-stage renal disease [92].
Few AS mouse models mimicking human clinical features have been developed [93–95].
Differences in the genetic background (e.g., C57BL/6 J or 129/Sv) are associated with different patterns
of disease progression, which suggests that animal models are useful to elucidate the underlying
mechanisms involved in the development and progression of the disease [96,97]. Furthermore,
pharmacological therapy such as that with angiotensin-converting enzyme (ACE) inhibitors was
shown to delay disease onset [98,99]. Importantly, various studies that take the mutant Col4a−/−
as a model of AS have shown the implication of oxidative stress in this pathology. Evidence of
oxidative stress is demonstrated by a significant rise in the urinary heme oxygenase-1 (HO-1)
and H2O2 excretion rate in the urine of Col4a3−/− mice compared with age-matched wild-type
controls [98,100]. Using dihydroethidium (DHE) staining as a marker of tissue ROS generation,
Gomez et al. demonstrated that kidneys from Col4a3–/– mice produce higher levels of mitochondrial
ROS together with a high concentration of H2O2 in the urine [100]. In Col4a3−/− hearts, oxidative stress
was markedly elevated, including 50% reduction in the GSH:GSSG ratio, as well as reductions in
the protein levels of the mitochondrial electron transport chain of complexes I, II, and IV and a
35% increase in malondialdehyde [101]. The results using RNA expression to compare the global
transcriptome of whole kidney and hearts from Col4a3−/− with littermate controls suggest that
metabolic and mitochondrial dysfunction are major problems in AS mouse. Prominent among the
downregulated genes in kidney were peroxisomal and mitochondrial fatty acid metabolism genes,
such as Acox2, mitochondrial genes, such as Pgc1 and the Cyp450 gene family, and the antioxidant
Mpv17l [100]. In hearts, the expression of Hbb-b1, Alas2, Cnn1, Aqp7, and Ogdhl genes was significantly
reduced in Col4a3−/− mice [101]. In addition, defective mitochondrial respiration has been observed in
primary tubular cells and in cardiomyocytes isolated from Col4a3−/− mice, as measured by oxygen
flux analysis [102]. Electron microscopy images revealed stressed mitochondrial morphology in the
Alport tubular renal cells and hearts [101,102]. In this context, two therapeutic approaches were taken
with similar results. Treatment of Col4a3−/− mice with anti-miR 21 that directly targets Mpv17l in
kidney increases lifespan and protects Col4a3−/− mice from kidney disease progression by preventing
miR-21-mediated suppression of the PPARα fatty acid metabolism and mitochondrial biogenesis
pathways and inhibition of mitochondrial ROS generation in the kidney [100]. Similarly, osteopontin
deficiency improves renal function and mitochondrial respiration in the renal tubules, which reduces
dynamin-3 expression [102] and the cardiac phenotype and myocardial mitochondrial respiration by
rescue of 2-oxoglutarate dehydrogenase-like protein (OGHDL) expression [101].
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3.1.2. Collagen VI-Associated Myopathies: Bethlem Myopathy, Ullrich Congenital Muscular
Dystrophy, and Myosclerosis Myopathy
Deficiency of collagen type VI (Col VI) caused by mutations of COL6 genes (COL6A1, COL6A2,
and COL6A3) gives rise to three main muscle disorders: Bethlem myopathy (BM), Ullrich congenital
muscular dystrophy (UCMD), and myosclerosis myopathy. BM is relatively mild with a later onset
and displays a relatively mild and slowly progressive phenotype. UCMD is severe and shows diffuse
wasting and weakness of skeletal muscles in the first year of life, associated with degeneration and
regeneration of muscle fibers with more rapid progression of symptoms and premature death due
to respiratory failure [103,104]. Myosclerosis is a nondystrophic myopathy characterized by early,
progressive muscle and joint contractures that result in severe limitation of movement of axial, proximal,
and distal joints, walking difficulties in early childhood, and toe walking. Muscle biopsy shows partial
collagen VI deficiency at the myofiber basement membrane and absent collagen VI around most
endomysial/perimysial capillaries [105].
Col VI myopathies share defective autophagy that impairs clearance of dysfunctional
mitochondria [106,107] as well as mitochondrial dysfunction due to deregulation of the permeability
transition pore (PTP), an inner membrane, high-conductance channel formed from dimers of the
mitochondrial ATP synthase [108–111]. The mitochondrial defect has been identified in skeletal
fibers and neurons of Col VI-null mice (Col6a1−/−) [108,112] and in myoblasts from UCMD and BM
patients [113,114]. Mitochondrial monoamine oxidases (MAO), a ROS generator, is increased in Col6a1
knock-out muscle. Not surprisingly, ROS production is higher in Col6a1 knock-out muscle than
control [115]. Additionally, suggesting a protective role for Col VI against age-induced oxidative
damage, ROS production was significantly higher in the brain of aged Col6a1−/− mice than in
age-matched, wild-type samples, whereas younger mouse brains did not reveal any significant
difference between the two genotypes [112].
Different therapies have been investigated for COL VI myopathies. Inhibition of cyclophilin D,
which modulates the opening of the PTP in the mitochondrial inner membrane, reduces myofiber
degradation and apoptosis in animal models of Col VI myopathy [110,116,117], cultured myoblasts [118],
and muscle biopsies from patients with Col VI myopathy treated with cyclosporin A [119].
Myoblasts from patients, upon incubation with H2O2 or tyramine (MAO substrate), upregulate MAO-B
expression and display a significant rise in ROS levels, with concomitant mitochondrial depolarization.
MAO inhibition by pargyline significantly reduced both ROS accumulation and mitochondrial
dysfunction. However, cyclosporine A could not prevent mitochondrial depolarization induced by
tyramine, suggesting that MAO-dependent ROS accumulation is upstream of PTP opening, and that
oxidative stress makes the latter event insensitive to cyclosporine A [120].
3.1.3. Collagen VIII-Associated Pathologies: Fuchs Syndrome
Fuchs endothelial corneal dystrophy (FECD) is a progressive, bilateral condition characterized by
dysfunction of the corneal epithelium, leading to reduced vision. The corneal endothelium is essential
for maintaining the transparency of the cornea by regulating corneal hydration. Ultrastructural features
of FECD include the loss of endothelial cells with thickening and excrescences of the underlying
basement membrane (i.e., guttae), which are clinical hallmarks of FECD, becoming more numerous
with the progression of the disease [121]. Genetic studies have identified multiple gene mutations
and loci associated with FECD. Mutations positioned in the triple helical domain of collagen type 8
(COL8A2) alter the structure and composition of Descemet’s membrane, leading to the early onset of
type I FECD [122–124]. Significant insights to understand Col 8 deposition in FECD and its relationship
with young onset of the disease have been obtained due to the development of Col8a1 knock-in [125,126]
and knock-out [127] mouse models.
Corneal tissues from FECD patients display an overall increase of ROS, and human corneal
endothelial cell lines derived from FECD patients are more vulnerable to oxidative insults (measured,
among others techniques, by human oxidative stress and antioxidant defense RT-PCR arrays,
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high-sensitivity ELISA to quantify 8-hydroxy-2′-deoxyguanosine, and immunofluorescence) [128].
The corneal endothelial cells present an inefficient mitochondrial system including increased
mitochondrial DNA damage, decreased mitochondrial membrane potential, and mitochondrial
fragmentation [129,130]. Enzymatic antioxidants like SOD in cytosolic and mitochondrial forms,
catalase, glutathione peroxidase, and glutathione reductase are also depleted in FECD [131].
Proteomic analysis of corneal endothelium from FECD patients showed specific downregulation
of the peroxiredoxin family of antioxidants (Prdx1 and Prdx6) [132–134] and NRF2 [135].
In a therapeutic approach, researchers try to restore ATP production by stabilizing cardiolipin,
a phospholipid present in the inner mitochondrial wall that is vulnerable to oxidative stress.
Elamipretide, a synthetic mitochondria-targeted tetrapeptide that ameliorates mitochondrial
dysfunction by preventing peroxidation of cardiolipin [136], is in phase II trials (Stealth Biotherapeutics
ClinicalTrials.gov Identifier: NCT02653391).
Interestingly, in addition to oxidative stress and apoptosis that are indicated as the underlying
mechanism for the progressive loss of endothelial cells in FECD [128], corneal samples from FECD [137,138]
and knock-in mouse models [125] show upregulation of the unfolded protein response (UPR) evidenced
by dilated ER, deregulated transcript levels of UPR markers (by PCR-array among the significant 42,
GRP78, phosphoeIF2α, CHOP, EDEM3) [137,138]. A treatment strategy could be a combination therapy.
Experiments to determine whether a reduction of ER stress could reduce dystrophic conditions and
restore corneal transparency would provide insight into therapeutic strategy. For example, lithium,
which can inhibit UPR and oxidative stress, promotes endothelial cell survival in the knock-in mouse
model of FECD [139].
3.1.4. Collagen XV-Associated Deficiencies
Genetic analyses have suggested that COL15A1 is associated with atherosclerosis in aged
individuals [140]. It can also act as a modifier of the severity of the thoracic aortic aneurysm [141]. It has
a potential role in primary open-angle glaucoma [142] and has been implicated in Cuticular drusen,
a subtype of age-related macular degeneration [143]. In the context of atherosclerosis, the expression of
Col15a1 in SMCs is interesting because COL15A1 affects both the proliferative and migratory phenotypes
of this cell type. Thus, Col15a1 knock-out in SMC markedly attenuated lesion formation by reducing
SMC proliferation and impairing multiple proatherogenic inflammatory processes [144]. Other studies
with knock-out mice have shown that collagen XV is important for the structure and function of
microvessels in the striated muscle, heart, and skin [145,146]. Mice subjected to exercise-induced
stress developed capillary rupture heart failure and muscle atrophy [145]. Under physiological
conditions, these mice exhibited a reduced cardiac ejection fraction at 1 month of age, which was
compensated at 5 months of age, by a still unknown mechanism [146]. Additional defects in
Col15a1−/− hearts included tortuous capillaries varying in thickness, frequent ruptures in the capillary
walls, poor capillary perfusion, and abnormal extravasated erythrocytes [146]. In the skin of these
mice, intravital microscopy revealed microvascular dysfunction including increased permeability,
a decreased capillary perfusion index, reduced blood cell velocity, and lower microvascular blood
flow rate [146]. Drosophila mutants of multiplexin (Mp), the orthologue of vertebrate collagen types
XV and XVIII, exhibited morphological changes in cardiomyocytes and progressive dysfunction of
the skeletal muscles, reminiscent of phenotypes observed in Col15a1-null mice [147]. Interestingly,
Mp fly mutants showed morphologically altered mitochondria in indirect flight muscles, resulting in
severely attenuated ATP production and enhanced ROS production. Mitochondria from Mp mutants
showed abnormal cristae, swollen appearances, and diffuse outer membranes, which are signs of
enhanced mitochondrial permeability due to mitochondrial PTP opening [108,148]. This suggests a
pathomolecular mechanism shared with COL6A1 mutations. Mitochondrial PTP opening is enhanced in
mutants, and Mp collagens are required for mitochondrial homeostasis. The progressive phenotypes of
MP-related diseases are attributable to mitochondrial dysfunctions [147]. Integrins mediating signaling
from Mp to mitochondria are in accordance with the biochemical evidence that integrins engage in
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the regulation of mitochondrial ROS production by Rho GTPases and Bcl-2 [149]. Mitochondrial
dysfunction resulting from collagen VI or XV/XVIII deficiencies were ameliorated by cyclosporin
A, an inhibitor of mitochondrial PTP opening or losartan, an angiotensin II type 1 receptor blocker.
This suggests a potential convergent mechanism and treatment [119,147].
3.2. Genetic Diseases Affecting Elastic Fibers and Associated Components
3.2.1. Elastin
The importance of elastin is highlighted by the variety of diseases caused by genetic alterations
in the ELN gene with clinical consequences ranging from mild to life-threatening. These genetic
alterations affect either the quantity or the quality of the deposited elastin and thereby affect the
function of elastic tissues [150]. Most reported mutations within the ELN gene cause supravalvular
aortic stenosis and autosomal dominant cutis laxa. More than 100 pathogenic or presumed pathogenic
variants have been described in ELN to date in the literature, according to the ClinVar database
(https://www.ncbi.nlm.nih.gov/clinvar) and the Human Gene Mutation Database (http://www.hgmd.
cf.ac.uk). The most common genetic alterations that affect the elastin gene are large deletions that remove
one copy of ELN in addition to the neighboring 25–27 genes as part of the recurrent microdeletion
disorder Williams–Beuren syndrome (WBS) [151].
Supravalvular Aortic Stenosis
Supravalvular aortic stenosis (SVAS) is a heart defect that develops before birth (1:20,000 newborns).
The condition is described as supravalvular because the section of the aorta that is narrowed is located
just above the aortic valve. This narrowing usually makes it difficult for blood to leave the heart,
which results in heart murmur and ventricular hypertrophy. Some people with SVAS also have defects
in other blood vessels, most often stenosis of the pulmonary artery. If SVAS is not treated, the aortic
narrowing usually leads to chest pain, shortness of breath, and, finally, to heart failure.
Most of the ELN gene mutations that cause SVAS result from a decrease in the production
of tropoelastin [152]. Due to the shortage of tropoelastin, elastic fibers of the tunica media of the
aorta become thinner. To compensate this, SMCs concomitantly increase in number (hyperplasia),
resulting in a thicker aortic wall that narrows the lumen. A thickened aorta is less flexible and, therefore,
less resistant to the stress of blood flow and pumping of the heart. Over time, there is a tendency to
develop high blood pressure. The severity of SVAS, even among members of the same family, is highly
variable. Strikingly, some affected individuals die in infancy, while others never experience symptoms
of the disorder.
Notably, changes in oxidative stress seems to contribute to cardiovascular dysfunctions in
individuals with elastin haploinsufficiency [153]. After a bioinformatic analysis of the quantitative
trait locus peaks, Ren1, Ncf1, and Nos1 significantly emerge as modifiers to predispose to hypertension
and stiffer blood vessels [154]. Elevated renin in Eln-deficient mice has been described [155]. Renin is a
major component of the renin-angiotensin pathway, whereas NO is important for influencing vascular
tone. Both have known effects on blood pressure. Higher oxidative stress in the elastin-insufficient
vessels has been correlated with Ncf1 overexpression [154] Ncf1 (encoding for p47phox) acts as a
regulatory subunit for several NOX family members that are expressed in the vasculature [156,157],
which contributes to the production of ROS.
Due to the dynamic and developmentally complex elastic fiber assembly, no therapy has been
reported so far that can restore normal elastin to those with elastin insufficiency. Thus, the identification
of genes that modify this pathology can serve as a basis for the identification of therapeutic strategies,
which are mostly lacking in these types of pathologies.
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Williams–Beuren Syndrome
Williams–Beuren syndrome (WBS) is a rare developmental disorder (1:10,000) with multisystemic
manifestations caused by segmental aneusomy of 1.55–1.83 Mb at chromosomal band 7q11.23,
which includes ELN and 25–27 additional genes (Williams–Beuren syndrome critical region, WBSCR).
Besides the characteristic face and cognitive profile, the hallmark feature of WBS is a generalized
narrowing of large elastic arteries, most notably SVAS, mainly due to ELN deficiency [158].
Histological characterization of arterial vessel walls of WBS patients shows increased number and
disorganized elastic lamellar structures, fragmented elastic fibers, and hypertrophy of SMCs [159].
Arteriopathy is the main cause of morbidity in WBS, including systemic hypertension and other
potential complications such as stroke, cardiac ischemia, and sudden death [160,161]. Differences in
the WBS deletion that affect the copy number for NCF1 finally affect hypertension risk on the severity
of vascular stiffness [162,163]. Studies performed in Ncf1 knock-out mice have revealed that p47phox
is one of the major effectors of Ang II [164], consequently Ang II-mediated oxidative stress in the
vasculature was the proposed mechanism behind this protective effect in patients whose deletion
includes a copy of NCF1 [162,165].
The entire WBSCR is conserved in mice on chromosome band 5G2 in reverse orientation with
respect to the centromere [166]. Two mouse strains were generated, each carrying half of the WBSCR
deletion. According to their location with respect to the centromere, the two half deletions were named
proximal deletion (PD, Gtf2i to Limk1) and distal deletion (DD, Limk1 to Trim50, including Eln) [167].
DD mice presented with generalized arteriopathy, increased blood pressure, increased vessel stiffness,
and cardiac hypertrophy [165,168]. Like humans, this cardiovascular phenotype has been associated
with elevated AngII, increased oxidative stress markers, and Ncf 1 expression. Treatments aimed at
reducing NOX activity either via decreasing Ncf1 gene dosage or pharmacologically with apocynin
and losartan treatment both improved hormonal and biochemical parameters in DD mice, resulting in
normalized blood pressure and improved cardiovascular histology [165].
A complete deletion (CD) model recapitulates the exact deletion observed in humans, in position
and gene dosage [169]. The cardiovascular phenotype of CD mice is milder than that of DD
mice [168,169], which suggests a modifying effect of gene(s) within or near the PD. Reduced expression
of Ncf1 was observed in affected tissues of CD mice [169,170]. Therefore, as in humans, Ncf1 is likely to
have an impact on blood pressure in this model.
Cardiac hypertrophy present in CD mice was associated with increased levels of oxidative
stress in the heart due to dysfunction of the NFR2 pathway. Chronic administration of the
antioxidant epigallocatechin-3-gallate (EGCG) rescues the hypertrophic cardiomyopathy, which restores
nuclear levels of NRF2 in correlation with normalization of mRNA expression of target genes [170].
The mechanism by which ROS formation is augmented in the hypertrophic heart is currently
unknown. Besides NADPH oxidases, there are several potential sources of superoxide anion formation,
including uncoupled NOS and mitochondria. In this regard, ascending aortas from CD mice show the
presence of luminal stenosis and compromised contractile responses to α1-adrenoceptor activation
associated with increased NO signaling. The increased nNOS signaling may act as a physiological
response against the detrimental effects of stenosis [171].
Recent studies also involve mitochondrial dysfunction in WS pathogenesis. In WS-derived
primary fibroblasts, decreased basal respiration and maximal respiratory capacity was found, as well
as increased ROS generation and decreased ATP synthesis [172]. This mitochondrial dysfunction could
be due to loss of DNAJC30, a gene included in the WBSCR. DNAJC30 knock-out mice showed reduced
ATP levels as well as alterations in mitochondrial function.
Cutis Laxa
Cutis laxa (CL) is a collection of disorders that are typified by loose and/or wrinkled skin that
leads to a prematurely aged appearance. Many CL-related genes have been identified to date such as
(1) genes in elastic fiber biogenesis (elastin), fibulin-4, fibulin-5, and latent TGFβ-binding protein 4,
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(2) genes required for intracellular protein trafficking (ATP7A, ATP6V0A2, and RIN2), and (3) genes
required for cellular metabolism (PYCR1, ALDH18A1, and SLC2A10) [173]. Only mutations in PYCR1
(ARCL2B) and SLC2A10 ATS (see below) have been related with oxidative balance. The loss of PYCR1
causes increased sensitivity to oxidative stress reflected by collapse of the filamentous mitochondrial
network, decreased mitochondrial membrane potential, and a five-fold increase in cell death [174].
SLC2A10, which encodes GLUT10, was shown to transport dehydroascorbate (oxidized vitamin C)
into mitochondria to limit the production of ROS [175]. Slc2a10 knock-down in zebrafish produces
disorganization of the vasculature, wavy notochord, and cardiac edema, as well as mitochondrial
dysfunction and reduced TGF-β signaling [176]. Thus, PYCR1 and SLC2A10 would be required to
maintain mitochondrial redox balance.
3.2.2. Fibrillins and Fibrillin-Associated Proteins
Mutations in fibrillins (fibrillin-1 or fibrillin-2) lead to heritable connective tissue disorders
known as fibrillinopathies such as Marfan syndrome (MFS), ectopia lentis (EL), Weill–Marchesani
syndrome (WMS), MASS syndrome (Mitral valve prolapse, Aortic root diameter at upper limits of
normal for body size, Stretch marks of the skin, and Skeletal conditions similar to Marfan syndrome),
Shprintzen–Goldberg syndrome (SGS), and acromicric (AD) and geleophysic (GD) dysplasias. However,
the molecular mechanisms that lead to their pathogenesis are less known, including the impact of ROS
and redox stress.
Marfan Syndrome
Marfan syndrome (MFS) is an autosomal dominant negative disease with a prevalence of
1:5000, without gender or ethnic predisposition and affecting multiple organs and systems including
cardiovascular, ocular, and skeletal ones. The most severe complications affect the cardiovascular
system, including aortic root and ascending aorta aneurysms and dissections, and mitral valve
regurgitation and prolapse. The lifespan of undiagnosed patients is around 40 years old, but this age is
rather variable depending on the mutation occurring in fibrilin-1 gene (FBN1) and other unknown
genetic and epigenetic determinants. The major ocular injury is ectopia lentis or the dislocation
of crystalline lenses and myopia. The skeletal characteristics are rather evident and are reflected
in high height (dolichostenomelia) due to overgrowth of long bones and longer and thin fingers
(arachnodactyly). Additionally, patients can show pectus deformities (pectus excavatum or pectus
carinatum), pes planus, and palate alterations [177,178]. Mutations in the FBN1 gene are the cause of
MFS and up to now almost 3000 mutations have been reported. Despite this large number, there is no
correlation between the location or type of mutation and the resulting clinical phenotype. Depending on
the FBN1 mutation, the resulting mutant fibrillin-1 will cause a dominant-negative or haploinsufficiency
effect in the disease, whose impact on the progress of the disease is poorly known, but it acquires
potential relevance about the efficacy of current pharmacological treatments [179].
As indicated above, the fatal hallmark of MFS is aortic aneurysm, which usually ends with the
dissection and rupture of the aorta. Whereas TGF-β has been postulated as an essential determinant
in the pathogenesis of the aneurysm, its role has recently been questioned [180–182]. Nonetheless,
it is now becoming clear that other molecular determinants significantly contribute to the aneurysm
disorder, such as overproduction of ROS and the subsequent oxidative stress-associated damage
to constituents of the aortic wall (tunica intima, media, and adventitia). Mice harboring mutations
of Fbn1 or Fbn2 have provided significant insights into the understanding of microfibril-associated
physiopathology. Nowadays there are several mice models bringing mutant forms of Fbn1 [183,184],
which lead to MFS (with several degrees of pathology). Through their use, it has been reported that
(1) fibrillins-1 and -2 form copolymers and fibrillin-1 is mandatory for the postnatal maturation and
mechanics of the aortic wall and (2) such copolymers regulate the availability of family members of
TGF-β and BMP and other differentiation factors [185].
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In human abdominal aortic aneurysms (AAA), dysregulated inflammation induction,
MMPs’ activity, SMCs’ apoptosis and/or phenotypic switching, and ECM remodeling contribute
to a variable extent to disease progression [186]. Nonetheless, the role of oxidative stress in AAA and in
thoracic aortic aneurysm and dissection (TAAD) is less known. However, there is increasing evidence
of its impact on the pathogenesis or progression of these conditions. Therefore, aortic aneurysms of
genetic origin are also probably affected by oxidative stress.
TAAD of genetic origin involves different genes, which can be subdivided into three groups
according to the (sub)cellular processes in which their encoded proteins are involved [187]:
(1) ECM homeostasis (COL1A1, COL3A1, COL5A1, LOX, MFAP5, and PLOD1), (2) TGF-β signaling
(TGFB2, TGFB3, TGFBR1, TGFBR2, SMAD2, SMAD3, and SKI), and (3) the SMC contractile apparatus
(ACTA2, MYH11, MYLK, PRKG1, and FOXE3). To date, only LOX, ACTA2, MYH11, and PRKG1 have
been shown to be associated with oxidative stress.
LOX encodes lysyl oxidases (LOXes) and it is the only TAAD-related gene acting at the ECM
that has been clearly linked to oxidative stress so far. LOXes are a group of ECM enzymes that
initiate the formation of covalent cross-linkages between collagen and elastin, generating H2O2 as a
by-product [188]. Experiments in Lox-deficient mice have shown that LOX-mediated cross-linking
is essential for the maturation of the ECM, providing tensile strength [189,190]. Elevated LOX
expression levels in a haploinsufficiency mouse MFS model (FBN1C1039G/+) correlated with the
prevention of larger dilation of the aneurysm. Administration of LOX inhibitors blocked collagen
accumulation and aggravated elastic fiber impairment, which initiated rapid progression of aneurysm
dilatation [191]. Interestingly, LOX has also been identified as a novel vascular ROS source in
hypertension. Thus, H2O2 produced because of LOX-induced cross-linking contributes to the
pathogenesis of the disease [192]. However, it is unclear why LOX seems to offer a protective role in TAAD
development yet causes oxidative stress in hypertension, whereas clinical manifestations of both diseases
clearly differ. MFS patients are usually normotensive or even slightly hypotensive, while hypertension is
characterized by high blood pressure levels, particularly diastolic blood pressure [193].
Other TAAD-associated genes regulate TGF-β signaling, which is a crucial signaling pathway
for embryonic development, cell differentiation and proliferation, apoptosis, and ECM production
and (re)modeling [194]. To date, deleterious effects in none of the TGF-β signaling-associated TAAD
genes are known to cause excessive ROS production. Nevertheless, it is well-established that TGF-β
signaling indirectly contributes to oxidative stress by stimulating ROS production and/or suppressing
antioxidant systems in fibrosis, tumorigenesis, and cerebral ischemia [195,196]. The contribution of
TGF-β-mediated oxidative stress has been demonstrated in MFS. This effect occurs through indirect
regulation of the expression of NADPH oxidase NOX4 in MFS patients and mice [197] (see below).
Under normal circumstances, differentiated SMC expresses contractile-associated markers such as
smooth muscle actin alpha 2 (ACTA2; encoding for α-SMA) and smooth muscle myosin heavy chain
11 (MYH11) [198,199]. Mutations in both of these genes are linked to TAA [187]. It is well known
that vascular injuries are characterized by excessive production of ROS that, among other stimuli, can
modulate SMC function and plasticity [200]. In such a pro-oxidant environment, contractile SMCs
undergo a phenotypic switch toward a more synthetic fibroblast-like cell. This state is characterized
by decreased expression of contractile-associated markers (e.g., α-SMA) and increased proliferation,
migration, and ECM synthesis. It has been established that TGF-β signaling plays a dual role in
SMC phenotypic switching in MFS [201]. However, the molecular mechanisms underlying oxidative
stress-mediated SMC phenotype switching in TAA and MFS have not been elucidated. Oxidative stress
can be both a cause and a consequence of loss of α-SMA. In vitro and ex vivo studies in human and
mice aortic tissue could correlate excessive ROS production with increased expression of connective
tissue growth factor (CTGF). Thus, oxidative stress regulates the SMC phenotype via CTGF [202].
NOX4 overexpression augments H2O2 levels, an effect that regulates both the differentiation of stem
cells into VSMCs and the phenotypic changes between contractile and synthetic states [203]. ROS also
switch VSMCs from a quiescent physiological contractile phenotype to a proliferative phenotype,
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which facilitates VSMCs’ migration, proliferation, and modification of the surrounding extracellular
matrix [204]. VSMCs from p22phox-overexpressing mice exhibit increased H2O2 production and
increased expression of synthetic phenotypic markers concomitantly with decreased contractile
markers [205]. H2O2 also induces miR-145 expression in VSMCs to promote a contractile differentiation
state [206], elevated ROS levels, and NOX4 expression in isolated VSMCs and aortic tissue derived
from Acta−/− mice [207]. The loss of α-SMA favors the synthetic state, and ROS accumulation promotes
NF-κB signaling, leading to increased expression of AngII receptor type 1a (AgRT1) [208]. Both TGF-β
and AngII signaling phosphorylate Smad2 and Erk1/2 to initiate aneurysm formation. Consistently,
losartan, an angiotensin receptor 1 inhibitor, prevented aortic aneurysm in MFS mice [209]. Of note,
losartan, together with atenolol, is a pharmacological strategy given to MFS patients despite its
demonstrated low efficiency in ameliorating aortic aneurysm [210,211]. A recent study in MFS mice has
identified α-SMA as a possible redox stress target [197]. The α-SMA can undergo redox modifications
(nitration and/or carboxylation), leading to impaired protein function. Thus, it can contribute to
aneurysm formation and/or development. Therefore, regardless of whether α-SMA is mutated or
not, oxidative stress seems to have a significant impact on SMC phenotype and function and, thus,
on aneurysm formation and/or progression.
More recently, gain-of-function mutations in PRKG1 have been associated with oxidative stress.
PRKG1 encodes for cGMP-dependent protein kinase 1, which is an essential mediator of VSMC tone
through NO/cGMP-signaling. Here, basal protein kinase G (PKG) activity was significantly increased
in mice carrying the PRKG1 mutation, which leads to oxidative stress, increased VSMC apoptosis,
and elastin fiber breaks [212].
Initial evidence for the contribution of oxidative stress in MFS came from a study examining
endothelial function in MFS mice [213]. The endothelial-dependent relaxation in TAAD segments of
Fbn1C1039G/+ mice was severely affected because of the downregulation of eNOS/AKT signaling-induced
NO. Subsequent preincubation of MFS aortic tissue with several ROS inhibitors improved acetylcholine
(Ach)-induced aortic relaxation. Simultaneously, protein expression levels of ROS-producing enzymes
XO, NOX, and iNOS increased with the concomitant reduction of SOD [214]. In another study,
endothelial dysfunction was prevented in Nox4-deficient MFS mice [197], which involved, for the first
time, NADPH oxidases in the progression of the MFS aortic aneurysm. In this study, MFS aortic tissue
and cultured SMC derived from MFS patients showed NOX4 overexpression. In a newly generated
MFS mouse model lacking Nox4 gene expression, the integrity of elastic fibers was preserved and aortic
aneurysm progression was significantly reduced. Remarkably, this finding was only significant in
9-month-old mice but not in younger mice. This suggests that NOX4 negatively influences aneurysm
progression in later stages of the disease [197]. A similar protective role of Nox4 has been reported in
cerebral arteries and aorta of Marfan mice and patients, respectively [215,216]. Altogether, an imbalance
between ROS-producing proteins, including NOX4, and ROS-scavenging proteins actively impairs
vasomotor function in MFS. Recently, besides eNOS, iNOS has been involved in MFS aneurysm
formation [217]. This group reported increased iNOS levels in MFS mice and human aortic tissue,
which were reverted after the administration of an iNOS inhibitor quickly normalized aortic size.
Ex vivo experiments using Fbn1C1039G/+ aortic tissue samples showed that imbalanced production
of COX-derived prostanoids, especially COX-2, also contributes to vasomotor dysfunction in MFS [218].
Moreover, the administration of a nonselective COX-inhibitor, indomethacin, to the hypomorphic
mouse MFS model (Fbn1mgR/mgR) efficiently attenuated elastin degeneration, inhibited macrophage
infiltration, and reduced MMP-2 and MMP-9 overexpression [219]. Interestingly, the contribution of
COX-2 in MFS (Fbn1C1039G/+)-induced aortic dysfunction was sex dependent, since aortic anomalies of
this enzyme were only detected in males [220]. These findings show that COX-2-derived prostanoids
influence vasomotor aortic function in MFS.
The role of oxidative stress in the pathophysiology of vascular alterations in MFS is becoming
clearer. Pioneer studies showed that FBN1 mutation in MFS mice (Fbn1mgR/mgR) was related to increased
ROS production together with increased TGF-β and p38 MAPK signaling [221]. Shortly afterwards,
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elevated oxidative stress levels in plasma and aortic homogenates (pooled ascending aorta and
aortic arch) were reported in Fbn1C1039G/+ mice [214] and MFS patients [222]. More recently,
a study demonstrated that ROS levels are exclusively increased in the dilated segments of the
aorta. Thus, ROS enhancement was only present in the ascending aorta of Fbn1C1039G/+ mutants and
not in the descending arm [223]. These results agree with the different impact that MFS produces in the
aortic reactivity of Fbn1C1039G/+ mice, in which it induces either increased or decreased α1 adrenergic
contractions in ascending and descending thoracic aorta, respectively [197]. Active phosphorylated
forms of SMAD2 and Erk1/2 only increased in the affected segments [180,224]. These results reinforce
the postulate that an interplay between TGF-β and ROS contribute to TAAD development. However,
we must bear in mind that different mice models of MFS might provide conflicting results. This is
the case of MFS mice (mg∆loxPneo), a MFS mouse model in which Fbn1 exons 19–24 were replaced by
a neomycin-resistant expression cassette [225]. Authors reported that, whereas ROS were enhanced
in later stages of aortic dilation, ROS reduction with lipoic acid did not prevent aortic dilation
and elastic fiber injuries. Therefore, oxidative stress was uncoupled from aortic wall injuries [226].
In Fbn1C1039G/+ mice, ROS inhibition with apocynin (an unspecific NADPH oxidase inhibitor) attenuated
aortic aneurysm progression and AngII-dependent enhanced ROS production in a TGF-β-dependent
manner [223].
Oxidative stress comes not only from sustained increases in ROS production over time, but also
from the reduced activity of scavengers from which glutathione is the main system. In aortic tissue from
MFS patients, it has been reported that reduced activity of glutathione-S-transferase and glutathione
peroxidase occurs, in conjunction with a decrease of reduced glutathione [227]. Therefore, the depletion
of scavengers with or without increases of ROS generation could aggravate the aortic aneurysm in MFS.
Mitochondrial-derived increased ROS production has recently been associated with cell senescence.
Aortic tissue and SMC isolated from MFS patients show accelerated senescence. This effect is at least
partly mediated by ROS-induced activation of NF-κB signaling [228].
Other important sources of ROS in the cardiovascular system are XO, NO, and COXes. XO links
purine metabolism to redox signaling and stress. UA and superoxide anion are the two main products
from XO activity. Elevated levels of serum UA in humans are often associated with an increased
risk of cardiovascular disease [229]. It is important to bear in mind that UA in physiological serum
concentrations acts as a powerful antioxidant in the blood by scavenging ROS [61,230]. UA accounts
for more than 50% of the total antioxidant capacity of biological fluids in humans [231]. UA was found
in the wall of human aortic aneurysms and atherosclerotic arteries [232]. These findings suggest that
UA might aggravate or attenuate the formation and/or progression of aortic aneurysms, including
those present in MFS [230]. Nevertheless, further research is needed to elucidate the exact role of UA
in MFS, as it is currently unknown whether it acts as an antioxidant or pro-oxidant.
Numerous therapeutic strategies are being investigated to fight against TAAD [233].
Therapies based on antioxidants have shown relative success, most probably due to the complexity
of multiple pathways that tightly regulate the balance between ROS production and scavenger
systems. In any case, their use deserves further attention considering recent results. This is the
case of cobinamide, an analog of the free radical-neutralizing vitamin B12, which prevented aortic
wall degeneration in a heterozygous mutant mouse for protein kinase G1 (PRKG1) that leads to its
overactivation. The antioxidant N-acetylcysteine also ameliorated the aortopathy in these mutant
mice [212]. Another promising example comes from the use of resveratrol in MFS [234]. Resveratrol is
a potent polyphenol that is present in high concentrations in plants, nuts, and the skin of grapes.
Treatment of MFS mice (Fbn1C1039G/+) with resveratrol reduced NOX4 expression and MMP2 activity
and changed eNOS/iNOS and miR21/miR29 balances, which improved SMC survival. Moreover,
resveratrol improved cardiomyocyte homeostasis, which probably activates mitochondrial sirtuin1
(SIRT)1 and increases SOD expression [235].
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Weill–Marchesani Syndrome
Fibrillin-1 is composed of individual domains like multiple tandem arrays of epidermal growth
factor-like domains (EGF-like domains) and cysteine-containing domains (TB domains). An RGD
(arg-gly-asp) motif that binds integrins is present in TB4 domain [236,237] and adjacent TB5 binds
heparin [238]. Different mutations in the TB5 domain cause autosomal dominant Weill–Marchesani
syndrome (WMS) or acromicric (AD) and geleophysic (GD) dysplasias [239]. In contrast to MFS,
these cause short stature, thickened skin, joint defects, and ocular problems. Unfortunately, very little
is known about the contribution of ROS and oxidative stress in these diseases. Nevertheless, in a small
cohort of WMS patients, plasma levels of lipid peroxide (LPO), TNF-α, and NO were elevated with a
concomitant reduction of antioxidant capabilities. This suggests that redox dysfunctions contribute to
the pathogenesis of WMS and point to antioxidants and free radical scavengers as a potential therapy
to ameliorate the disease [240].
Systemic Sclerosis
Tissue fibrosis is the hallmark of systemic sclerosis (SSc) and the uncontrolled wound-healing
process. Systemic sclerosis (SSc) or scleroderma is a chronic autoimmune disease characterized by
tissue fibrosis and immune abnormalities, and the most common form of acquired scleroderma [241].
It is characterized by progressive thickening and hardening of skin and multiple internal organs.
Inflammatory infiltrates and fibrosis of blood vessels in the dermis precede human SSc. Tsk/+ (tight-skin)
mice have evidenced dysfunctions of fibrillin-1 microfibrils in SSc in the dermis, particularly fibrillin-1
aggregates and fragmented elastic fibers [242]. It is well known that oxidative stress linked to
vascular injury plays an important role in the pathogenesis of SSc [243–247]. Circulating levels
of ROS and related markers correlate with SSc vasculopathy, fibrosis onset, and autoantibodies’
production [248]. The excess of ROS stimulates endothelial injury and other vascular alterations,
which activate TGF-β-mediated EMT, a process that converts endothelial cells into myofibroblasts [249].
ROS cause chemical modifications in some lipids, proteins, and nucleic acids [250], which generate
new epitopes that induce strong autoimmune responses. This is what has been shown in SSc,
with ROS-associated changes in gene expression pattern and the stimulated release of IL-6, IL-8, and IL17
among others [251,252]. In this respect, diverse therapeutic strategies to interfere with ILs’ expression
and/or their release have been successfully addressed with drugs such as the phosphodiesterase type 5
inhibitor sildenafil [253], the natural flavonoid kaempferol [254], EGCG [255], and the anti-IL-6 receptor
antibody tocilizumab [256], among other treatments [257]. Many of these treatments also have an
antioxidative stress effect that reduces or prevents the characteristic abnormal accumulation of ROS in
this disease [258]. Other antioxidants, such as hydrogen sulfide, have been reported to interfere in the
onset and progression of this disease [259]. NRF2, a transcription factor that induces the transcription
of antioxidant genes (for example GSH) is downregulated in cultured skin fibroblasts derived from
SSC patients. This observation was confirmed in both skin and lungs of SSc mice. Treatment with the
NRF2 agonist dimethyl fumarate (DMF) reduced fibrosis and immune overactivation [260]. One of
the main sources of ROS in SSC are NADPH oxidases [261,262]. Increased NOX2 and NOX4 have
been reported in SSC fibroblasts, neutrophils, monocytes, and T lymphocytes [263–265]. In addition,
NOX4 is highly expressed in skin of SSc patients and in cultured SSc fibroblasts. This overexpression is
triggered by TGF-β via PKCδ and Smad2/3 [266].
Loeys–Dietz Syndrome
Loeys–Dietz syndrome (LDS) is not a disorder caused by mutations in CT structural components,
but CT is severely affected because mutations in the TGF-β receptor or SMAD3 have a strong impact on
the homeostasis of this tissue [267]. Despite the different disease etiologies, LDS clinical manifestations
are related to MFS in the vascular system because of TGF-β signaling pathway dysregulation.
LDS results from heterozygous substitutions in crucial residues of the kinase domains of types I or II
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TGF-β receptor or Smad3, which theoretically abrogates TGFβ signaling. Paradoxically, such signaling
remains hyperactivated. Much less is known about LDS in comparison with other syndromes, and even
less regarding ROS and oxidative stress contribution to the pathology. Nevertheless, a couple of recent
studies provide evidence of their involvement. In a similar study previously carried out in MFS patients,
the content of enzymatic and nonenzymatic systems involved in redox stress was measured in plasma
and TAA from LDS patients [268]. This group observed a significant reduction of antioxidative stress
mechanisms (GSH, antioxidant capacity, glutathione peroxidase, glutathione-S-transferase, catalase,
and thioredoxin reductase) accompanied by an increase in both SOD and XO activities. Moreover,
NRF2 expression decreased, which explains the reduced expression or activity of antioxidant enzymes.
In addition, reduced mitochondrial respiration was observed in cultured SMC from the mouse model
of LDS (TGFBR1M318R/+). Cultured human fibroblasts from LDS and Marfan patients also showed
lower oxygen consumption [269].
Arterial Tortuosity Syndrome
Arterial Tortuosity Syndrome (ATS) is a heritable disease characterized by twisting and lengthening
of the major arteries, hypermobility of the joints, and laxity of skin [270]. ATS is caused by mutations
in SLC2A10, which encodes Glucose Transporter 10 (GLUT10) [271]. In ATS, loss of GLUT10 results
in defective collagen and/or elastin. Two models explain the onset and development of the disease:
(1) The loss of GLUT10 induces a glucose-dependent increase in TGFβ that stimulates cell proliferation
in the vessel wall and (2) GLUT10 transports ascorbate (vitamin C), an essential cofactor for collagen
and elastin hydroxylases, into the secretory pathway [272]. Considering the essential connection
between ascorbate and the redox state of cells (mainly in fibroblasts), the latter hypothesis acquires
more relevance. GLUT10 is highly expressed in VSMC and adipocytes, where it facilitates the transport
of the oxidized form of vitamin C (1-dehydroascorbic acid, DHA) into mitochondria, which protects
against oxidative stress. The loss of function of GLUT10 in a mutant mouse showed much higher
mitochondria-generated ROS levels than wild-type mice [175]. Transcriptomic analysis of cultured skin
fibroblasts from ATS patients showed an increase in lipid peroxidation sustained by PPARγ function.
The rescue of normal GLUT10 expression normalized redox homeostasis, PPARγ activity, and TGF-β
signaling, accompanied by partial ECM reorganization [273]. These works highlight the relevance of
vitamin C and ROS in arterial abnormalities.
3.3. Proteoglycans and Glycosaminoglycans
Hyaluronic acid (HA) is a widely distributed nonsulfated GAG and a major component of the
cartilage extracellular matrix and synovial fluid. An oxidative stress environment of elevated OH•
and ONOO•−, and increased lipid peroxidation, is associated with HA fragmentation. This effect
contributes to the inflammatory response in chondrocytes [274]. In addition, HA can be cleaved by
hypochloric acid in autoimmune diseases [275]. HA can also have anti-inflammatory and antioxidative
actions in chondrocytes [276] by a mechanism involving AKT–NRF2 axis activation [277] Overall,
the role of HA during oxidative and inflammatory damage seems to depend on the size of the
HA molecule. High-molecular-weight HA provides tissue integrity and low-molecular-weight HA
mediates inflammatory responses [278]. However, ROS are also involved in genetic pathologies that
affect the biological cycle of proteoglycans (see below).
Mucopolysaccharidoses
Alterations in GAGs’ degradation occur with an intra-lysosomal accumulation of nondegraded
products, which cause a group of lysosomal storage disorders called mucopolysaccharidoses (MPS).
The degradation of GAGs requires 10 different enzymes that have been widely studied: Five sulfatases,
four glycosidases, and one nonhydrolytic transferase. Deficiencies have been found in each of them,
resulting in seven MPS that share a series of clinical characteristics, though to varying degrees [279,280].
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Typical manifestations include skeletal and joint deformities, dysmorphic facial characteristics,
dwarfism, and, depending on type and severity, intellectual disabilities, spinal cord compression,
increased intracranial pressure, ocular and hearing impairment, respiratory difficulties,
gastrointestinal pathology, and umbilical or inguinal hernias [281–284]. GAGs are normal components
of large vessels and cardiac valves [285–287]. Deposition of GAGs occurs in the myocardium,
the cardiac valves, and the coronary arteries of all types of MPS, resulting in diffuse narrowing of
the epicardial coronary arteries, cardiac valve dysfunction, ventricular hypertrophy, and cardiac
failure [288]. The most prominent cardiac manifestation present in 60–90% of patients is progressive
cardiac valve pathology. Although it is most prominent in MPS I and MPS II, coronary artery narrowing
and/or occlusion has been described in individuals with all types of MPS. Large vessels in patients
may show increased wall thickness and may either be narrowed or dilated. Systemic hypertension due
to arterial narrowing is common among individuals with MPSI and MPSII. In addition, dilation of
the ascending aorta and markedly reduced aortic elasticity has been reported in MPS I. This could be
attributed to the downstream effects of GAGs on the assembly of tropoelastin, resulting in elastin that
is decreased in content and abnormal in structure [288].
Available evidence on lysosomal diseases shows increased ROS production, dysfunctional
mitochondria, aberrant inflammatory and apoptotic signaling, and perturbed calcium homeostasis,
among other biochemical alterations [289]. An abnormal accumulation of nondegraded GAGs within
the lysosomes leads to ROS increase. Given the acidic interior of lysosomes and abundance of the
reducing amino acid cysteine, lysosomes would be a perfect environment to foster Fenton-type
reactions, making them unusually sensitive to oxidative stress. The disruption of lysosomes can cause
a release of hydrolases, undegraded metabolites and iron into the cytosol, causing cell apoptosis or
necrosis, and, finally, tissue injury. Additionally, in a loop process, the release of lysosomal content
induces secondary ROS production in cytoplasm, which aggravates the oxidative stress [290–292].
The involvement of ROS has been reported in MPS pathology. MPS I patients show high lipid
peroxidation levels [293]. Furthermore, MPS II patients show global impairment in redox status,
evidenced by an increase in lipids and protein oxidation, as well as alterations in SOD and catalase
activities [294]. Accumulation of oxidative products are frequent in MPS IIIB [295]. A reduction
of antioxidant defense systems together with oxidative-induced DNA, lipid, and protein damage
have been described in MPS IVA disease [296]. Cells exposed to oxidative stress enhance the
antioxidant defenses in an attempt to reestablish homeostasis. MPS I mice showed increased carbonyl
groups and elevated SOD and CAT activities together with a decrease of thiobarbituric acid-reactive
substances, which suggests an exposure to oxidative stress in this model [297]. An increase in oxidative
damage-related hallmarks coincides with GAGs’ accumulation as very early events in MPS II mice
pathogenesis and precedes glial degeneration, which finally leads to neuronal death. Additionally,
the anomalous mitochondrial pattern observed in astrocytes supported the presence of oxidative
damage in MPS II progression [298].
An upregulation of NADPH and pro-inflammatory cytokines in MPS IIIB knock-out mice due to
microglia activation has been reported [299]. Intense production of superoxide anion, whose main
sources during inflammatory conditions are NOXes 1 and 2, enhances the production of other ROS,
such as H2O2 and ONOO−, which enhances the oxidant environment [300]. As a result, an increase
of ROS and NOS occurs due to microglial Nox and iNOS activation [301,302]. In MPS IIIA mice,
a potential link between inflammation and oxidative stress has also been reported [303]. In animal
models of MPS VI and VII, an inflammatory process caused by intralysosomal accumulation of GAGs
has been postulated, which could trigger the release of cytokines, chemokines, proteases, and NO,
leading to apoptosis and connective tissue destruction [304]. Pro-inflammatory cytokines can induce
the production of oxidants, prostaglandins, and mitochondrial ROS by macrophages, which contributes
to the damage found in MPS patients [305].
Enzyme replacement therapy (ERT) with recombinant human enzymes is a treatment that intends
to deliver sufficient enzyme activity to reduce and prevent the accumulation of undegraded substrates.
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This therapeutic strategy has been used in patients with MPS types I (laronidase), II (idursulfase-α),
IVA (elosulfase-α), and VI (galsulfase) [306,307].
MPS IVa patients with ERT presented oxidative and inflammatory imbalance even after eight
months of ERT treatment [296]. In MPS II patients, a protective effect against oxidative stress was
observed during the first six months of ERT treatment [294]. Nevertheless, even during long-term
ERT, some degree of inflammation, oxidative, and nitrative imbalances occur in these patients.
These alterations seem to be induced by GAGs’ accumulation and pro-inflammatory cytokines.
Notwithstanding, ERT is known to reduce GAGs’ levels and was efficient at improving several
biomarkers of oxidative stress [308]. After six months of gene therapy in a mouse model of MPS
IIIb, there was a significant reduction in the expression of Ccl3, which plays an important role in
the macrophage-dependent inflammatory response. There were also reductions in the inflammatory
caspase Casp 4 and in Cybb (gp91phox), which is a component of the phagocytic enzyme complex
NADPH oxidases [309]. Many studies suggest that as a complement of ERT, antioxidant drugs could
be candidates to delay disease onset and progression. Neural stem cell cultures of an MPS II mouse
model treated with vitamin E triggered full rescue of the phenotype, both of mutant glial and neuronal
cells [298]. In fibroblast of MPS III patients, the accumulation of GAGs was partially restored by
supplementation with CoQ10 or an antioxidant cocktail (α-tocopherol, N-acetylcysteine, and α-lipoic
acid). The efficacy varied, depending on the characteristics of each patient, but the results were
encouraging [310].
4. Concluding Remarks
Redox reactions are necessary for the normal physiology of cells, tissues, and organs.
Redox constituents and their products (radical species) have important autocrine- and, probably,
paracrine-signaling functions. Radical species generated at cellular level have a great impact on cellular
components (lipids, proteins, and nucleic acids), whose functions can significantly change in the short
or long term depending on how long the radicals are present in the cell environment. It is evident that
when radicals are constantly produced and exceed the buffering capacity of endogenous antioxidants,
the physiological role of ROS becomes detrimental, which leads to oxidative stress. In this review,
we examined the impact of ROS and oxidative stress in genetic diseases of CT. ROS and oxidative
stress are involved in the CT pathology of different genetic diseases at molecular and cellular levels.
They have gained relevance in ECM organization and dynamics because ECM (re)modeling is always
determinant in the normal homeostasis of the tissue and associated pathologies. Due to increasing
awareness of this factor, new therapeutic antioxidant approaches are applied to many of these reported
diseases to halt or mitigate clinical symptoms and/or progression of the examined disease. However,
this is not easy because oxidative stress can be generated by the dysregulated production of ROS or by
dysfunctions of the scavenger systems. In the end, the results might be the same (i.e., oxidative stress),
but identification of the precise mechanism by which oxidative stress is generated is essential for a
successful therapeutic approach. Further work is necessary to understand the real impact of oxidative
stress on the generation and/or progression of genetic diseases (in this case, those affecting connective
tissue). Pharmacological interference of oxidative stress in genetic diseases that affect CT formation
deserves more attention.
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